April 22

Born in 1825 in Vilnius, Aronson managed a successful family business. He collected and documented Jewish tales, proverbs, and customs from his homeland. Aronson published several Yiddish works that became valuable records of Eastern European Jewish life. Beyond literature, he held patents for practical agricultural and mechanical inventions. His dual career bridged commerce and culture in 19th-century Lithuania. He died on April 22, 1893, remembered for his contributions to business and Jewish heritage.

Born in 1812, Meik studied engineering during Britain's industrial expansion. He established a firm specializing in docks, harbors, and railway projects. Under his leadership, the company completed major infrastructure works across the UK. Meik's innovative approaches to coastal engineering earned widespread respect. His firm later evolved into the Halcrow Group, influencing global engineering practices. He died on April 22, 1896, leaving a lasting corporate legacy and mentorship tradition.

Henry Royce was an English engineer and entrepreneur who co-founded Rolls-Royce Limited with Charles Stewart Rolls in 1904. He began his career repairing electrical equipment before designing his own precision machinery. Royce's dedication to engineering excellence led to the development of the legendary Rolls-Royce Silver Ghost automobile. He also oversaw engine development during World War I, producing aero engines that powered Allied aircraft. Under his guidance, Rolls-Royce set new standards in reliability and quality that endure today. Royce was knighted in 1930 for his achievements in engineering and industry. He passed away in 1933, leaving a legacy of innovation that shaped the automotive world.

George Rathmann was an American scientist and businessman who played a pivotal role in the birth of the biotechnology industry. With a Ph.D. in chemistry, he led research at companies like Exxon Biomedical Sciences before co-founding Applied Molecular Genetics, later known as Amgen, in 1980. Under his leadership as CEO, Amgen developed groundbreaking therapies such as erythropoietin (EPO) for anemia and granulocyte colony-stimulating factor (G-CSF). Rathmann's vision helped transform genetic research into viable medical treatments. After stepping down, he continued to support biotech innovation as an investor and advisor. His legacy endures in the life-saving drugs he helped bring to market.